SGCB and endothelial dysfunction: Similarly, therapies targeting NO-sGC-cGMP signaling (e.g., vericiguat) exemplify pathway-specific interventions that are mechanistically aligned with endothelial dysfunction-dominant HFpEF endotypes [134].